Hyphens Pharma International Limited (1J5.SI)

0.2750 0.0000 (0.00%) At close: 11:53AM SGT

Hyphens Pharma International Limited

16 Tai Seng Street
Level 4
Singapore 534138
Singapore
65 6338 8551
https://www.hyphensgroup.com

Sector(s): Healthcare
Industry: Pharmaceutical Retailers
Full-time employees: 422

Key executives

Name	Title	Pay	Exercised	Year born
Mr. See Wah Lim	Executive Chairman & CEO	N/A	N/A	1969
Mr. Yufan Zhang	Chief Financial Officer	N/A	N/A	N/A
Mr. Yann Alain Marche	Chief Operating Officer	N/A	N/A	N/A
Jessica Tan	Chief People Officer	N/A	N/A	N/A
Ms. Stella Ang	Head of Regulatory Affairs	N/A	N/A	N/A
Mr. Jamal Iflizar	Country Head of Indonesia	N/A	N/A	N/A
Mr. Ang Francis	Country Head of Malaysia	N/A	N/A	N/A
Josiephine Sac Mantoya	Country Head of Philippines	N/A	N/A	N/A
Laurence Fremy	Country Head of Vietnam	N/A	N/A	N/A
Ms. Sher Mei Lim C.A.	Company Secretary	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SGD.

Description

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, family medicine, and general surgery. The Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products. This segment offers dermocosmetic products under the Ceradan and TDF brands through medical professionals; health supplement products under the Ocean Health brand directly to consumers via retail channels; and scalp care products under the CG 210 brand through medical professionals. The Medical Hypermart and Digital segment wholesales pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. The segment also operates an online B2B platform; and WellAway, an e-pharmacy. In addition, it offers PLINEST and NEWEST Polynucleotides-HPTTM products; OXITHION, a skin brightening solution; and Nabota, a highpurity botulinum toxin. Further, the company provides pharmaceutical products, nutraceuticals, and medical devices for hospitals, polyclinics, specialists, and general practitioners. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.

Corporate governance

Hyphens Pharma International Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.